Clinical Trial Update: RethinQ Study - Evaluating Pacing in Heart Failure Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update for Abbott's RethinQ pacing system evaluating therapy in heart failure patients; the study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• RethinQ Pacing System

Snippet

Sponsor: Abbott Medical Devices | Conditions: Heart Failure | Phase 3 | Status: COMPLETED